Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE PRESERVATIVE FREE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE PRESERVATIVE FREE versus WESTADONE.
FENTANYL CITRATE PRESERVATIVE FREE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic opioid agonist; primarily binds to mu-opioid receptors in the CNS, modulating nociceptive pathways and producing analgesia, sedation, and euphoria.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Initial: 50-100 mcg IV every 2-5 minutes as needed for pain. For anesthesia: 2-50 mcg/kg IV bolus, then 0.7-10 mcg/kg/hr infusion.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in healthy adults, but may be prolonged to 4–12 hours in elderly, critically ill, or obese patients due to increased volume of distribution and decreased clearance. Context: Duration of action after a single bolus is relatively short due to redistribution, but accumulation can occur with repeated doses or infusions, leading to prolonged effects.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily hepatic metabolism via CYP3A4, with approximately 75% of the dose excreted in urine as metabolites (primarily norfentanyl) and <10% as unchanged fentanyl. About 9% is excreted in feces. Minimal biliary excretion.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist